List of Excipients in Branded Drug CARISOPRODOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	CARISOPRODOL	carisoprodol	51525-5901	ALGINIC ACID
Mylan Pharmaceuticals Inc	CARISOPRODOL	carisoprodol	51525-5901	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	CARISOPRODOL	carisoprodol	51525-5901	POTASSIUM SORBATE
Mylan Pharmaceuticals Inc	CARISOPRODOL	carisoprodol	51525-5901	STARCH, CORN
Mylan Pharmaceuticals Inc	CARISOPRODOL	carisoprodol	51525-5901	TRIBASIC CALCIUM PHOSPHATE

Generic Drugs Containing CARISOPRODOL

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	METHYLCELLULOSE
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	POVIDONE K30
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	SILICON DIOXIDE
Hikma Pharmaceuticals USA Inc	carisoprodol	0143-1176	SODIUM LAURYL SULFATE

What are the Most Frequently-Used Excipients in CARISOPRODOL?

# Of NDCs	Excipient
1	ALGINIC ACID
17	ANHYDROUS LACTOSE
100	CELLULOSE, MICROCRYSTALLINE
3	COLLOIDAL SILICON DIOXIDE
74	CROSCARMELLOSE SODIUM
8	CROSPOVIDONE
7	DOCUSATE SODIUM

Carisoprodol Excipient Strategy and Commercial Opportunities: Formulation, Regulatory, and Patent Analysis

Last updated: August 7, 2026

Carisoprodol is a mature generic skeletal-muscle relaxant with limited conventional patent protection and low formulation complexity. The strongest commercial opportunities are not in a new conventional tablet, but in differentiated delivery systems, abuse-deterrent designs, pediatric or geriatric dosage forms, improved tolerability, and combination products. Any reformulation must address carisoprodol’s controlled-substance status, its metabolism to meprobamate, dose-related sedation, and the FDA’s requirements for bioequivalence and inactive-ingredient safety.

What is the current commercial and regulatory status of carisoprodol?

Carisoprodol is an FDA-approved centrally acting skeletal-muscle relaxant indicated for acute, painful musculoskeletal conditions as an adjunct to rest and physical therapy. It is marketed primarily as immediate-release tablets in 250 mg and 350 mg strengths. The recommended treatment duration is generally limited to two or three weeks because longer-term effectiveness has not been established and dependence, withdrawal, and misuse risks increase with extended exposure (FDA, 2024a).

Attribute	Current position
Active ingredient	Carisoprodol
Primary indication	Acute musculoskeletal pain
Common strengths	250 mg and 350 mg tablets
Dosage form	Immediate-release oral tablet
Key active metabolite	Meprobamate
FDA controlled-substance status	Schedule IV
Original approval	1959
Primary U.S. market	Generic prescription products
Reference product	Soma
Main commercial constraint	Mature generic pricing and controlled-substance risk
Main formulation opportunity	Differentiated delivery, safety, and patient-use profiles

Carisoprodol is metabolized in part by CYP2C19 to meprobamate, a pharmacologically active metabolite associated with sedative and anxiolytic effects. Pharmacokinetic variability is therefore relevant to excipient selection, especially where an excipient could alter gastric emptying, intestinal transit, dissolution, or hepatic exposure (FDA, 2024a).

The drug’s low molecular weight and established oral absorption make it technically suitable for conventional tablets, orally disintegrating tablets, multiparticulates, and modified-release systems. The commercial value of a new formulation depends on demonstrating a clinically meaningful benefit rather than simply changing tablet appearance or excipient identity.

What excipients are used in approved carisoprodol tablets?

Approved carisoprodol products use standard oral-solid-dose excipients. Product-specific inactive ingredients vary by manufacturer and strength. Common categories include diluents, binders, disintegrants, lubricants, glidants, and colorants.

Excipient category	Examples reported in carisoprodol products	Formulation function
Diluent	Lactose, dibasic calcium phosphate, microcrystalline cellulose	Tablet mass and manufacturability
Binder	Povidone, pregelatinized starch	Granule and tablet strength
Disintegrant	Corn starch, sodium starch glycolate, crospovidone	Tablet breakup
Lubricant	Magnesium stearate	Ejection and tooling protection
Glidant	Colloidal silicon dioxide	Powder flow
Colorant	FD&C dyes, iron oxides	Product identification
Film coating	Hypromellose, polyethylene glycol, titanium dioxide	Appearance and swallowability

DailyMed labeling shows that inactive ingredients differ among carisoprodol manufacturers. Some products contain lactose, while others use calcium phosphate or cellulose-based fillers. This variation creates room for products designed for lactose avoidance, low-moisture processing, direct compression, or improved physical robustness without changing the active ingredient (National Library of Medicine, 2024a; National Library of Medicine, 2024b).

Which excipients have the greatest commercial relevance?

The most commercially relevant excipient strategies are:

1. Lactose-free formulations for patients with lactose intolerance or manufacturers seeking simplified excipient declarations.
2. Direct-compression platforms using microcrystalline cellulose and high-functionality disintegrants.
3. Low-dust formulations for manufacturing and handling control.
4. Taste-masked multiparticulates or orally disintegrating tablets.
5. Hydrophilic or lipid-based matrices for modified release.
6. Polymer-coated particles for abuse-deterrent or tamper-resistant dosage forms.

Excipient substitution alone normally does not create durable market exclusivity. A patent must claim a non-obvious composition, process, performance profile, or therapeutic use.

What formulation patents could protect a carisoprodol product?

A new carisoprodol product could potentially obtain patent protection in five technical areas:

Patent area	Potential claim subject	Commercial objective
Modified release	Matrix, coated pellets, osmotic system, or multiparticulate profile	Reduce peak sedation or dosing frequency
Abuse deterrence	Gel-forming polymer, crush resistance, extraction resistance	Reduce misuse and support premium positioning
Rapid disintegration	Orally disintegrating tablet or porous solid	Improve administration without water
Taste masking	Ion exchange, polymer coating, complexation, or flavor system	Improve adherence and alternative administration
Combination formulation	Carisoprodol with an analgesic or anti-inflammatory agent	Product differentiation and regimen simplification
Manufacturing process	Granulation, coating, particle engineering, or stability process	Improve yield, content uniformity, or shelf life

A patentable formulation would need more than the selection of a conventional excipient. A claim based only on “carisoprodol plus lactose,” “carisoprodol plus magnesium stearate,” or a routine binder substitution would face substantial novelty and obviousness risk.

Stronger claim strategies would define measurable performance characteristics, such as:

• A specified dissolution profile.
• A controlled ratio of immediate-release and extended-release fractions.
• Resistance to crushing or solvent extraction.
• Reduced peak-to-trough exposure.
• Improved stability under accelerated conditions.
• A defined particle-size distribution.
• A release profile linked to reduced sedation or improved tolerability.

When does carisoprodol lose exclusivity?

Carisoprodol’s original composition-of-matter and basic product exclusivity have expired. The drug was approved in the United States in 1959, and the modern market is dominated by generic immediate-release products. No active ingredient exclusivity protects conventional carisoprodol tablets.

Exclusivity type	Status for conventional carisoprodol
New chemical entity exclusivity	Expired
Original composition patent	Expired
Conventional tablet exclusivity	No meaningful current protection
Pediatric exclusivity	No broadly relevant current protection identified
Orphan exclusivity	Not applicable
Generic competition	Established
New formulation exclusivity	Possible only through a separately developed product

The commercial question is therefore not whether a company can sell carisoprodol, but whether it can obtain regulatory and patent differentiation around a new product profile.

What is the Orange Book status of carisoprodol?

The Orange Book identifies approved drug products and certain relevant patents and regulatory exclusivities. Conventional carisoprodol immediate-release tablets are broadly genericized, and their commercial position is not supported by a current branded patent moat comparable to newer small-molecule products (FDA, 2024b).

A company developing a new carisoprodol formulation would need to evaluate:

• Whether the product is an ANDA-suitable version of an existing reference product.
• Whether a new drug application is required because the dosage form or pharmacokinetic profile is materially different.
• Whether the formulation contains a new active-ingredient combination.
• Whether a patent could be listed in the Orange Book.
• Whether the product has a distinct labeling claim that supports method-of-use protection.

A formulation patent may be Orange Book-listable if it claims an approved drug product and satisfies applicable FDA listing requirements. A process patent generally does not provide the same Orange Book position as a product or use patent.

What Paragraph IV challenges and generic entry risks exist?

Conventional carisoprodol tablets have high generic-entry risk because the product is old, the dosage form is simple, and multiple manufacturers already produce equivalent tablets. A new branded formulation would face two different competitive threats.

Threat to a conventional tablet

A conventional 250 mg or 350 mg immediate-release tablet would be vulnerable to:

• ANDA filings relying on the established reference product.
• Paragraph IV challenges to any newly listed formulation patent.
• Rapid price erosion after multiple generic launches.
• Limited prescriber willingness to switch from low-cost generic tablets.

Threat to a differentiated formulation

A modified-release, abuse-deterrent, or orally disintegrating product could have a stronger commercial position, but the patent estate would face:

• Obviousness attacks based on known modified-release technologies.
• Arguments that the formulation is an aggregation of routine excipients.
• Design-around using different polymers, coating weights, or release mechanisms.
• Bioequivalence disputes involving partial-area pharmacokinetic parameters.
• Challenges to the clinical relevance of claimed tolerability benefits.

For a branded formulation, a Paragraph IV strategy would be expected if a generic applicant believes it can invalidate the patent, avoid infringement, or show that the patent is not properly listed. Litigation risk is highest where the product depends on a narrow polymer ratio, coating thickness, dissolution range, or method-of-use claim.

How strong is the patent estate for a new carisoprodol formulation?

The patent estate for conventional carisoprodol is weak because the active ingredient and basic tablet platform are old. A new formulation estate could be moderate if it combines composition, process, and use claims with credible clinical differentiation.

Patent layer	Expected strength
Active ingredient	Very weak; expired technology
Conventional immediate-release tablet	Weak
Simple excipient substitution	Weak to moderate
Orally disintegrating tablet	Moderate, dependent on technical evidence
Modified release	Moderate, with substantial obviousness exposure
Abuse-deterrent design	Moderate to strong if performance is demonstrated
Combination product	Moderate, subject to obviousness and clinical support
Manufacturing process	Moderate if process produces unexpected quality or stability benefits
Method of use	Moderate, but dependent on approved labeling and clinical evidence

The strongest portfolio structure would claim the composition, the manufacturing process, the dissolution or abuse-deterrence performance, and a clinically relevant use. A single narrow formulation patent would leave substantial design-around exposure.

What excipient strategies could create new commercial opportunities?

Modified-release carisoprodol

A modified-release product could seek less frequent administration or lower peak concentrations. Potential technologies include hydrophilic matrix polymers, coated multiparticulates, ion-exchange systems, and osmotic platforms.

The technical challenge is balancing exposure with the drug’s intended short-term use. A longer-acting product could improve convenience but also extend sedation and exposure to a controlled substance. A new product would require a strong pharmacokinetic and clinical rationale.

Abuse-deterrent carisoprodol

Carisoprodol’s Schedule IV status and conversion to meprobamate create a rationale for abuse-deterrent development. Potential approaches include:

• Crush-resistant tablets.
• Polymer systems that form a viscous gel when crushed and mixed with liquid.
• Sequestered formulations that limit extraction.
• Aversion systems that produce an unpleasant effect when manipulated.
• Multiparticulates that preserve release control after mechanical abuse attempts.

FDA’s abuse-deterrent guidance focuses on laboratory, pharmacokinetic, and clinical evidence. An abuse-deterrent formulation does not eliminate abuse risk, and labeling claims require evidence under FDA standards (FDA, 2015).

Orally disintegrating tablets

An orally disintegrating tablet could target patients who have difficulty swallowing conventional tablets. Key formulation requirements include rapid disintegration, acceptable taste, mechanical strength, low friability, and adequate stability.

Carisoprodol is not an obvious candidate for a pediatric product because of sedation, dependence, and the limited duration of indicated use. The more commercially credible population is adults with swallowing difficulty or patients who need administration without water.

Taste masking is essential. Suitable approaches may include polymer-coated particles, ion-exchange resins, cyclodextrin complexation, or multiparticulate compression. A simple sweetener and flavor system may be insufficient if the drug has a strong or persistent taste.

Lactose-free and excipient-minimized tablets

A lactose-free product could offer a modest commercial distinction, especially for institutional buyers and patients who avoid lactose. The strategy has low patent strength but low development risk.

A clean-label product could use microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide, and magnesium stearate. Mannitol may support mouthfeel in orally disintegrating systems but can introduce cost, hygroscopicity, or compression considerations.

Combination products

Combining carisoprodol with acetaminophen, ibuprofen, or another analgesic could simplify treatment. The strategy carries significant regulatory and safety risk because it may increase sedation, gastrointestinal toxicity, hepatic exposure, or misuse potential.

A combination product would require evidence that the components provide a rational therapeutic benefit at appropriate doses. It would also face competition from separate low-cost generic products.

How does carisoprodol compare with competing muscle relaxants?

Drug	Common regulatory position	Formulation opportunity	Commercial constraint
Carisoprodol	Schedule IV; generic	Abuse deterrence, ODT, modified release	Meprobamate metabolism and dependence risk
Cyclobenzaprine	Generic; multiple oral forms	Extended release, ODT	Heavy generic competition
Tizanidine	Generic; tablets and capsules	Modified release, adherence platforms	Hypotension and hepatic monitoring
Methocarbamol	Generic	Oral disintegration and combination products	Mature low-price market
Baclofen	Generic; oral and intrathecal use	Modified release, liquid formulations	Different indication profile
Orphenadrine	Generic	Combination and extended release	Anticholinergic tolerability

Carisoprodol has a weaker long-term commercial profile than products with broader chronic indications because its approved use is short term. Its main differentiator is the possibility of designing around misuse, sedation, administration convenience, or dose frequency.

What FDA regulatory pathway would apply to a new carisoprodol formulation?

The regulatory pathway depends on how materially the product differs from existing tablets.

Product concept	Likely pathway
Same-strength conventional tablet	ANDA
Different inactive ingredients with same performance	ANDA, subject to FDA requirements
Orally disintegrating tablet	ANDA or NDA, depending on reference-product suitability
Modified-release product	Likely ANDA only if an appropriate reference and equivalence pathway exists; otherwise NDA
Abuse-deterrent formulation	NDA or supplemental NDA strategy, with abuse-deterrence evidence
Carisoprodol combination product	NDA or applicable combination-product pathway
New indication	NDA or supplemental NDA

A reformulator must evaluate inactive-ingredient safety, dissolution, food effect, pharmacokinetics, dose proportionality, metabolite exposure, and abuse-related endpoints. Controlled-substance manufacturing, distribution, recordkeeping, and post-market controls also apply through the Drug Enforcement Administration.

What manufacturing and intellectual-property barriers affect carisoprodol?

Manufacturing barriers are manageable for standard tablets but increase sharply for differentiated products.

Conventional tablets

The main risks are:

• Content uniformity.
• Lubrication sensitivity.
• Tablet hardness and friability.
• Blend segregation.
• Moisture-related stability.
• Scale-up reproducibility.

Modified-release systems

The critical variables are:

• Polymer grade and viscosity.
• Coating weight gain.
• Particle-size distribution.
• Pore-former concentration.
• Compression force.
• Dissolution sensitivity to food and alcohol.

Abuse-deterrent systems

The key manufacturing challenges include uniform polymer distribution, reproducible mechanical strength, extraction resistance, and control of release after crushing or chewing.

These technical parameters can support process patents and trade secrets. Trade-secret protection may be more durable than narrow formulation patents where manufacturing know-how is difficult to reverse engineer.

Which licensing and partnering opportunities exist?

No major current licensing transaction is required to commercialize a conventional generic carisoprodol tablet. Licensing opportunities are more likely in platform technology than in the active ingredient itself.

Potential partners include:

• Excipient suppliers with abuse-deterrent polymers.
• Drug-delivery companies with multiparticulate or osmotic platforms.
• Contract development and manufacturing organizations with controlled-substance capabilities.
• Generic manufacturers seeking a differentiated product.
• Specialty-pharma companies with pain, musculoskeletal, or addiction-risk portfolios.

A licensing deal would be more defensible if it includes formulation patents, manufacturing know-how, regulatory data, and a defined commercial territory. A bare license to use a common excipient is unlikely to justify significant royalty economics.

What generic launch scenarios exist?

Scenario 1: Conventional generic tablet

This is the lowest-risk and lowest-margin path. It requires established bioequivalence and manufacturing capability but provides limited pricing power.

Scenario 2: Lactose-free or excipient-minimized tablet

This offers modest differentiation with limited patent protection. The product may gain institutional or patient preference but remains exposed to generic substitution.

Scenario 3: Orally disintegrating tablet

This creates a clearer patient-use benefit and may support branded-generic positioning. Taste masking and mechanical robustness are the main technical risks.

Scenario 4: Modified-release product

This offers the highest potential value among non-combination formulations but carries greater clinical, pharmacokinetic, and patent risk.

Scenario 5: Abuse-deterrent product

This has the strongest strategic rationale but requires costly development and evidence. Commercial uptake depends on payer coverage, prescriber acceptance, and whether the product receives meaningful labeling differentiation.

What is the revenue exposure and competitive outlook?

Revenue exposure for a conventional product is likely to be limited by:

• Multiple generic competitors.
• Low switching costs.
• Short treatment duration.
• Controlled-substance prescribing restrictions.
• Price-based pharmacy substitution.
• Safety concerns involving opioids, benzodiazepines, alcohol, and other central nervous system depressants.

A differentiated product could command a premium only if it demonstrates a benefit that payers, prescribers, or health systems can recognize. The most credible value propositions are reduced misuse potential, easier administration, lower peak-related sedation, or lower dosing frequency. Excipient substitution without a patient or manufacturing benefit is unlikely to support premium pricing.

Key Takeaways

• Carisoprodol’s conventional composition and immediate-release tablet technology are long off-patent.
• Standard generic tablets have low patent strength and high price competition.
• The most promising excipient strategies are abuse deterrence, modified release, orally disintegrating dosage forms, and lactose-free or excipient-minimized products.
• A new formulation patent should claim measurable performance, not merely a routine excipient combination.
• Carisoprodol’s conversion to meprobamate and Schedule IV status create both a safety liability and a rationale for abuse-deterrent development.
• Modified release could improve convenience but may increase concerns about prolonged sedation and controlled-substance exposure.
• Licensing value is concentrated in delivery platforms, manufacturing know-how, and regulatory data rather than in carisoprodol itself.
• A differentiated product requires stronger clinical and pharmacokinetic evidence than a conventional generic tablet.

Frequently Asked Questions

Can a new carisoprodol excipient combination receive a patent?

Yes, but the combination must satisfy novelty and non-obviousness requirements. A routine substitution of lactose, starch, povidone, or magnesium stearate is unlikely to provide strong protection without unexpected performance.

Is carisoprodol suitable for an abuse-deterrent formulation?

Yes, technically. Its Schedule IV status, misuse potential, sedative effects, and meprobamate metabolite provide a rationale, but FDA labeling requires evidence that the formulation resists relevant abuse methods.

Would a lactose-free carisoprodol tablet receive market exclusivity?

Usually not. A lactose-free composition may be commercially useful, but the formulation would need unexpected technical properties or a non-obvious composition to support meaningful patent protection.

Can an orally disintegrating carisoprodol product be launched through an ANDA?

Possibly, depending on the applicable reference product, dosage-form equivalence, bioequivalence requirements, and FDA pathway. A materially different release profile or clinical use could require an NDA-based strategy.

Does carisoprodol have biosimilar risk?

No. Carisoprodol is a small-molecule drug, not a biologic. Its competitive threat comes from generic ANDA products, reformulated products, and combination products rather than biosimilars.

References

1. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. U.S. Department of Health and Human Services. https://www.fda.gov/media/84819/download

2. Food and Drug Administration. (2024a). Soma (carisoprodol) prescribing information. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/drugsatfda_docs/label/

3. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. National Library of Medicine. (2024a). DailyMed: Carisoprodol tablet, 250 mg. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

5. National Library of Medicine. (2024b). DailyMed: Carisoprodol tablet, 350 mg. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

6. Drug Enforcement Administration. (2024). Controlled substance schedules. U.S. Department of Justice. https://www.dea.gov/drug-information/drug-scheduling